JP4783275B2 - 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 - Google Patents
洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 Download PDFInfo
- Publication number
- JP4783275B2 JP4783275B2 JP2006343824A JP2006343824A JP4783275B2 JP 4783275 B2 JP4783275 B2 JP 4783275B2 JP 2006343824 A JP2006343824 A JP 2006343824A JP 2006343824 A JP2006343824 A JP 2006343824A JP 4783275 B2 JP4783275 B2 JP 4783275B2
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- hydrates
- ivabradine
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
・ 希釈剤として:乳糖、デキストロース、スクロース、マンニトール、ソルビトール、セルロース、グリセロール、
・ 滑沢剤として:シリカ、タルク、ステアリン酸ならびにそのマグネシウム塩およびカルシウム塩、ポリエチレングリコール、
・ 結合剤として:ケイ酸アルミニウムおよびケイ酸マグネシウム、デンプン、ゼラチン、トラガカント、メチルセルロース、カルボキシメチルセルロースナトリウムおよびポリビニルピロリドン、
・ 崩壊剤として:寒天、アルギン酸およびそのナトリウム塩、発泡性混合物。
それぞれイバブラジン10mgおよびアムロジピン5mgを含む錠剤1000個についての調製処方:
イバブラジン塩酸塩 10g
ベシル酸アムロジピン 5g
乳糖一水和物 62g
ステアリン酸マグネシウム 1.3g
ポビドン 9g
無水コロイドシリカ 0.3g
セルロースグリコール酸ナトリウム 30g
ステアリン酸 2.6g
実施例1
・ ジヒドロピリジン系カルシウムアンタゴニストで処置されており、(カルシウムアンタゴニストにかかわらず)苦痛のある狭心症発作を依然として訴える患者で実施された二つの臨床試験は、イバブラジンとの同時処置がこれらの発作を大いに実質的に(約60%)低減できることを示した。
組み入れ時およびイバブラジンを1年間投与されたときの、ジヒドロピリジンを投与されている患者における狭心症発作回数の変化
100患者年の曝露あたりのアムロジピン単独またはアムロジピン+イバブラジンの組み合わせで処置された冠状動脈患者における有害事象
Claims (6)
- 選択的かつ特異的な洞房結節If電流阻害剤であるイバブラジン、すなわち3−{3−[{[(7S)−3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル]メチル}(メチル)アミノ]プロピル}−7,8−ジメトキシ−1,3,4,5−テトラヒドロ−2H−3−ベンゾアゼピン−2−オン、またはその水和物、結晶形態、もしくは薬学的に許容される酸との付加塩のうちの一つ、およびカルシウム阻害剤であるアムロジピン、またはその水和物、結晶形態もしくは薬学的に許容される酸との付加塩のうちの一つを含むアンギナの処置のための医薬組成物。
- 選択的かつ特異的な洞房結節If電流阻害剤が、イバブラジン、すなわち3−{3−[{[(7S)−3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル]メチル}(メチル)アミノ]プロピル}−7,8−ジメトキシ−1,3,4,5−テトラヒドロ−2H−3−ベンゾアゼピン−2−オンの塩酸塩、またはその水和物もしくは結晶形態のうちの一つである、請求項1記載の医薬組成物。
- カルシウム阻害剤が、ベシル酸アムロジピンまたはその水和物もしくは結晶形態のうちの一つである、請求項1記載の医薬組成物。
- イバブラジン塩酸塩、またはその水和物もしくは結晶形態のうちの一つと、ベシル酸アムロジピン、またはその水和物もしくは結晶形態のうちの一つとを含む、請求項1記載の医薬組成物。
- 有効成分として、選択的かつ特異的な洞房結節If電流阻害剤であるイバブラジン、すなわち3−{3−[{[(7S)−3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル]メチル}(メチル)アミノ]プロピル}−7,8−ジメトキシ−1,3,4,5−テトラヒドロ−2H−3−ベンゾアゼピン−2−オン、またはその水和物、結晶形態、もしくは薬学的に許容される酸との付加塩のうちの一つ、およびカルシウム阻害剤であるアムロジピン、またはその水和物、結晶形態もしくは薬学的に許容される酸との付加塩のうちの一つを、それだけで、または一つ以上の薬学的に許容される賦形剤と組み合わせて含む、請求項1から4のいずれか一項記載の医薬組成物。
- 有効成分として、ベシル酸アムロジピン、またはその水和物もしくは結晶形態のうちの一つと組み合わせたイバブラジン塩酸塩、またはその水和物もしくは結晶形態のうちの一つを、それだけで、または一つ以上の薬学的に許容される賦形剤と組み合わせて含む、請求項5記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0513008A FR2894826B1 (fr) | 2005-12-21 | 2005-12-21 | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
FR0513008 | 2005-12-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010263499A Division JP2011068661A (ja) | 2005-12-21 | 2010-11-26 | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007169284A JP2007169284A (ja) | 2007-07-05 |
JP4783275B2 true JP4783275B2 (ja) | 2011-09-28 |
Family
ID=37075950
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006343824A Active JP4783275B2 (ja) | 2005-12-21 | 2006-12-21 | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 |
JP2010263499A Pending JP2011068661A (ja) | 2005-12-21 | 2010-11-26 | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010263499A Pending JP2011068661A (ja) | 2005-12-21 | 2010-11-26 | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 |
Country Status (41)
Country | Link |
---|---|
US (3) | US20070142356A1 (ja) |
EP (1) | EP1800683B1 (ja) |
JP (2) | JP4783275B2 (ja) |
KR (1) | KR100907584B1 (ja) |
CN (1) | CN101015556B (ja) |
AP (1) | AP2208A (ja) |
AR (1) | AR058575A1 (ja) |
AT (1) | ATE488239T1 (ja) |
AU (1) | AU2006252211B2 (ja) |
BR (1) | BRPI0605516A (ja) |
CA (1) | CA2571649C (ja) |
CO (1) | CO5790167A1 (ja) |
CR (1) | CR8813A (ja) |
CY (1) | CY1111007T1 (ja) |
DE (1) | DE602006018247D1 (ja) |
DK (1) | DK1800683T3 (ja) |
EA (1) | EA013536B1 (ja) |
ES (1) | ES2356660T3 (ja) |
FR (1) | FR2894826B1 (ja) |
GE (1) | GEP20094603B (ja) |
GT (1) | GT200600523A (ja) |
HK (1) | HK1106442A1 (ja) |
HR (1) | HRP20110028T1 (ja) |
IL (1) | IL180209A (ja) |
JO (1) | JO2675B1 (ja) |
MA (1) | MA28724B1 (ja) |
MX (1) | MXPA06014884A (ja) |
MY (1) | MY143563A (ja) |
NO (1) | NO337509B1 (ja) |
NZ (1) | NZ552222A (ja) |
PE (1) | PE20071133A1 (ja) |
PL (1) | PL1800683T3 (ja) |
PT (1) | PT1800683E (ja) |
RS (1) | RS51534B (ja) |
SA (1) | SA06270482B1 (ja) |
SG (1) | SG133546A1 (ja) |
SI (1) | SI1800683T1 (ja) |
TW (1) | TWI373344B (ja) |
UA (1) | UA91507C2 (ja) |
WO (1) | WO2007077329A2 (ja) |
ZA (1) | ZA200610822B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011068661A (ja) * | 2005-12-21 | 2011-04-07 | Lab Servier | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2920773B1 (fr) | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2927538B1 (fr) | 2008-02-14 | 2010-02-19 | Servier Lab | Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant. |
CN101564394B (zh) * | 2008-04-21 | 2010-12-15 | 鲁南制药集团股份有限公司 | 含有伊伐布雷定和曲美他嗪的药物组合物 |
WO2009158005A1 (en) * | 2008-06-27 | 2009-12-30 | Concert Pharmaceuticals, Inc. | Benzazepinone compounds |
FR2938194B1 (fr) * | 2008-11-07 | 2012-08-31 | Servier Lab | Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
US20030092745A1 (en) * | 2000-02-25 | 2003-05-15 | Pfizer Inc. | Combination therapy |
JP4194095B2 (ja) * | 2001-09-11 | 2008-12-10 | 旭化成ファーマ株式会社 | 脳血管障害、心疾患の予防・治療用医薬組成物 |
AR037565A1 (es) * | 2001-11-21 | 2004-11-17 | Synthon Bv | Formas de sales de amlodipina y procedimientos para prepararlas. |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2894826B1 (fr) * | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
-
2005
- 2005-12-21 FR FR0513008A patent/FR2894826B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-14 CR CR8813A patent/CR8813A/es not_active Application Discontinuation
- 2006-12-15 MA MA29539A patent/MA28724B1/fr unknown
- 2006-12-18 SG SG200608806-6A patent/SG133546A1/en unknown
- 2006-12-18 PE PE2006001618A patent/PE20071133A1/es active IP Right Grant
- 2006-12-18 MX MXPA06014884A patent/MXPA06014884A/es active IP Right Grant
- 2006-12-18 AP AP2006003858A patent/AP2208A/xx active
- 2006-12-19 NO NO20065903A patent/NO337509B1/no not_active IP Right Cessation
- 2006-12-20 MY MYPI20064723A patent/MY143563A/en unknown
- 2006-12-20 IL IL180209A patent/IL180209A/en active IP Right Grant
- 2006-12-20 SA SA06270482A patent/SA06270482B1/ar unknown
- 2006-12-20 EA EA200602156A patent/EA013536B1/ru unknown
- 2006-12-20 WO PCT/FR2006/002805 patent/WO2007077329A2/fr active Application Filing
- 2006-12-20 AT AT06291991T patent/ATE488239T1/de active
- 2006-12-20 AR ARP060105640A patent/AR058575A1/es not_active Application Discontinuation
- 2006-12-20 PL PL06291991T patent/PL1800683T3/pl unknown
- 2006-12-20 UA UAA200613551A patent/UA91507C2/ru unknown
- 2006-12-20 GE GEAP20069773A patent/GEP20094603B/en unknown
- 2006-12-20 CO CO06127373A patent/CO5790167A1/es not_active Application Discontinuation
- 2006-12-20 RS RSP-2010/0554A patent/RS51534B/en unknown
- 2006-12-20 EP EP06291991A patent/EP1800683B1/fr active Active
- 2006-12-20 GT GT200600523A patent/GT200600523A/es unknown
- 2006-12-20 TW TW095148015A patent/TWI373344B/zh not_active IP Right Cessation
- 2006-12-20 SI SI200630854T patent/SI1800683T1/sl unknown
- 2006-12-20 ES ES06291991T patent/ES2356660T3/es active Active
- 2006-12-20 DK DK06291991.5T patent/DK1800683T3/da active
- 2006-12-20 PT PT06291991T patent/PT1800683E/pt unknown
- 2006-12-20 DE DE602006018247T patent/DE602006018247D1/de active Active
- 2006-12-20 NZ NZ552222A patent/NZ552222A/en not_active IP Right Cessation
- 2006-12-21 CA CA2571649A patent/CA2571649C/fr active Active
- 2006-12-21 JP JP2006343824A patent/JP4783275B2/ja active Active
- 2006-12-21 ZA ZA200610822A patent/ZA200610822B/xx unknown
- 2006-12-21 KR KR1020060131725A patent/KR100907584B1/ko active IP Right Grant
- 2006-12-21 US US11/643,046 patent/US20070142356A1/en not_active Abandoned
- 2006-12-21 CN CN2006100643177A patent/CN101015556B/zh not_active Expired - Fee Related
- 2006-12-21 BR BRPI0605516-8A patent/BRPI0605516A/pt not_active Application Discontinuation
- 2006-12-21 JO JO2006490A patent/JO2675B1/en active
- 2006-12-21 AU AU2006252211A patent/AU2006252211B2/en not_active Ceased
-
2007
- 2007-11-05 HK HK07111993.7A patent/HK1106442A1/xx not_active IP Right Cessation
-
2009
- 2009-04-22 US US12/386,687 patent/US20090215745A1/en not_active Abandoned
-
2010
- 2010-11-26 JP JP2010263499A patent/JP2011068661A/ja active Pending
- 2010-11-29 CY CY20101101086T patent/CY1111007T1/el unknown
-
2011
- 2011-01-17 HR HR20110028T patent/HRP20110028T1/hr unknown
- 2011-05-13 US US13/068,551 patent/US20110230466A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011068661A (ja) * | 2005-12-21 | 2011-04-07 | Lab Servier | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4783275B2 (ja) | 洞房結節If電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 | |
JP5480202B2 (ja) | 心不全の処置における洞房結節If電流阻害剤およびアンギオテンシン変換酵素阻害剤の組み合わせの使用 | |
JP4705564B2 (ja) | 洞房結節If電流阻害剤およびアンギオテンシン変換酵素阻害剤の新規な組み合わせならびにそれを含む医薬組成物 | |
JP4874482B2 (ja) | アスピリンを含有する医薬組成物 | |
KR101078133B1 (ko) | 동방 결절 if 흐름 억제제와 베타 차단제의 회합체 | |
JPWO2019170136A5 (ja) | ||
WO1996031238A1 (fr) | Agent pour organes circulatoires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100617 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101129 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110510 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110705 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110708 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140715 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4783275 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |